Drug intelligence / Profile preview

Clone-7

Development stage: Preclinical
Lead developer: Adnexus Biotechnologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Clone-7 is a monoclonal antibody in preclinical development by Adnexus Biotechnologies for the treatment and prevention of HIV/AIDS. It was identified using the company's proprietary AI-driven platform, which targets conserved and immutable viral regions to ensure broad neutralization across diverse HIV clades and strains. While the specific epitope targeted by Clone-7 has not been publicly disclosed, the antibody is part of a portfolio of human-derived biologics developed from the immune cells of individuals who have effectively controlled HIV infection. The candidate is intended to provide a potent therapeutic or prophylactic option that overcomes the high mutability of the HIV virus.

Other names: Clone 7Clone7Clone-7

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on Clone-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clone-7.

Explore the full profile